Form 8-K - Current report:
SEC Accession No. 0001193125-26-119844
Filing Date
2026-03-23
Accepted
2026-03-23 16:32:38
Documents
10
Period of Report
2026-03-23
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-20260323.htm   iXBRL 8-K 49641
2 EX-99.1 stro-ex99_1.htm EX-99.1 176780
  Complete submission text file 0001193125-26-119844.txt   346948

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stro-20260323.xsd EX-101.SCH 26371
13 EXTRACTED XBRL INSTANCE DOCUMENT stro-20260323_htm.xml XML 4527
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 26782714
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)